Chronic Liver Diseases Therapeutics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	180 Pages	Coherent Market Insights	August, 2023	CMI18163370

Best Price Guarantee
Price	from $4,500
Length	180 Pages
Publisher	Coherent Market Insights
Published Date	August, 2023
SKU	CMI18163370

Chronic Liver Diseases Therapeutics Market, By Treatment Type Antiviral Drugs, By Disease Type, By Distribution type, And By Region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

This report provides an in-depth analysis of the global chronic liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
Antiviral drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Liver Diseases Therapeutics, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Astellas Pharma Inc
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

1. Research Objective and Assumption: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Treatment Type; Market Snippet, By Disease Type; Market Snippet, By Distribution type; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Drug Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Chronic Liver Diseases Therapeutics Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2018–2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019–2030; Segment Trends; Antiviral Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Immunosuppressants; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Vaccines; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Immunoglobulins; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Corticosteroids; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Targeted Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends; Chemotherapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Segment Trends
6. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2018–2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019–2030; Segment Trends; Hepatitis; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Autoimmune Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Non-alcoholic Fatty Liver Disease (NAFLD); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Genetic Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
7. Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2018–2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019–2030; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
8. Global Chronic Liver Diseases Therapeutics Market, By Regions, 2018–2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019–2030; Segment Trends; North America; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); Brazil; Mexico; Argentina; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn); North Africa; Central Africa; South Africa
9. Competitive Landscape: Company Profiles; Astellas Pharma Inc; Company Overview; Product Portfolio; Key Highlights; Financial Overview; Strategies; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline Plc; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi S.A; Pfizer Inc.; Takeda Pharmaceutical; Valeant Pharmaceuticals; Watson Pharmaceuticals, Inc.; Theratechnologies Inc.; Alnylam Pharmaceuticals, Inc.; Protagonist Therapeutics, Inc.; Dicerna Pharmaceuticals, Inc.; Endo International; Provectus Biopharmaceuticals Inc.; MAX BioPharma, Inc.
10. Section: References; Research Methodology; About us and Sales Contact; *Browse 30 market data tables and 24 figures on “Chronic Liver Diseases Therapeutics Market– Global forecast to 2030